Open AccessSafety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK)
Author(s) -
K. L. Neuhaus,
R. von Essen,
Ulrich Tebbe,
Andreas Jessel,
H. Heinrichs,
W Mäurer,
W Döring,
D Harmjanz,
V. Kötter,
E Kalhammer
Publication year - 1994
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/01.cir.90.4.1638
Subject(s) - medicine , thrombolysis , hirudin , heparin , myocardial infarction , partial thromboplastin time , bolus (digestion) , anesthesia , discovery and development of direct thrombin inhibitors , timi , antithrombin , randomized controlled trial , surgery , thrombin , platelet
Adjunctive therapy for thrombolysis in acute myocardial infarction consists of platelet inhibition with aspirin and thrombin inhibition with heparin. Thrombin inhibition may be improved by the use of hirudin as indicated by experimental and phase II clinical studies. The randomized, double-blind phase III r-Hirudin for Improvement of Thrombolysis study (HIT III) compared a recombinant hirudin (HBW 023) with heparin. The primary end point was the incidence of death or reinfarction.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom